Skip to content

A Prospective Randomized Controlled Trial: Comparison of Biochemical, Skin Temperature and Postoperative Functional Results Between Traditional Total Hip Arthroplasty And Robotic-Arm Assisted Total Hip Arthroplasty

A Prospective Randomized Controlled Trial: Comparison of Biochemical, Skin Temperature and Postoperative Functional Results Between Traditional Total Hip Arthroplasty And Robotic-Arm Assisted Total Hip Arthroplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059963
Enrollment
Unknown
Registered
2022-05-14
Start date
2022-05-02
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases with indications for total hip arthroplasty

Interventions

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 ~ 80 years old, regardless of gender; 2.Patients who meet the requirements of total hip arthroplasty and need the primary total hip arthroplasty according to the evaluation of the researchers; 3.The subjects fully understand the benefits and risks of this trial and are willing to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with neuromuscular dysfunction (e.g. paralysis, myolysis or abductor weakness) that can lead to postoperative hip instability or abnormal gait; 2.Active infection lesions in the hip joint or other parts of the body; 3.Patients with severe hip deformity and hip dysplasia with Crowe grade 3 or 4; 4. Ankylosing spondylitis patients with bony ankylosis or severe stiffness; 5. Patients with bilateral hip arthroplasty at the same time, or patients with contralateral hip arthroplasty within 3 months, or patients with contralateral hip arthroplasty expected to be performed within 1 year after operation; 6. The patient known to have a history of allergy to one or more implanted materials; 7. Patients with severe internal and surgical diseases or weak physique and unable to tolerate surgery; 8. Patients with poor expected compliance; 9. Pregnant or lactating women, or patients with family planning during clinical research; 10.The patient participating in other drug clinical trials within 3 months before enrollment, or other device clinical trials within 1 month before enrollment; 11. Other circumstances that the researchers consider inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
CRP (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);

Secondary

MeasureTime frame
ESR (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);IL-6 (within 7 days before operation, 6h after operation, 1 day after operation, 3 days after operation and 21 days after operation);Cortisol (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation and 21 days after operation);Lactate dehydrogenase (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);Creatine kinase (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation and 21 days after operation);Alkaline phosphatase (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);Serum amyloid A (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation and 21 days after operation);Leukocyte count (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);Percentage of lymphocytes (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation) ;Percentage of monocytes (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);HCT (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);Hemoglobin (within 7 days before operation, 6 hours after operation, 1 day after operation, 3 days after operation, 21 days after operation);Active hip flexion angle (within 7 days before operation, 3 days after operation and 21 days after operation);Active hip abduction angle (within 7 days before operation, 3 days after operation and 21 days after operation) ;Standing and walking test (within

Countries

China

Contacts

Public ContactZongke Zhou

West China Hospital of Sichuan University

zhouzongke@scu.edu.cn+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026